Major constraints in the hospital-treated infections drug market include generic erosion

The hospital-treated infections (HTI) drug market, the loss of patent protection for key branded products - notably Pfizer’s Zyvox (linezolid), the HTI sales leader in 2011 - and the continued generic erosion of premium-priced agents such as meropenem (Cubist Pharmaceuticals/AstraZeneca’s Merrem/Meronem; Dainippon Sumitomo’s Meropen; generics) as well as increasingly stringent regulatory and reimbursement environments will be the major constraints of market growth through 2021, according to a new report for health care advisory firm Decision Resources.

The Pharmacor advisory service entitled Hospital-Treated Infections finds that, over the next decade, the HTI market will grow at a modest 2.7% annual rate in the USA, France, Germany, Italy, Spain, the UK and Japan. This growth will be driven primarily by the uptake of 12 emerging therapies and continued use of premium-priced agents that target multidrug-resistant (MDR) pathogens.

Need for more convenient dosing being recognized